Palo Alto, CA · Founded 2018 · Privately Held (backing)
Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. GEn1E Lifesciences is based in Palo Alto, CA and was founded in 2018. It was valued at $136 million at its early-stage round in Dec 2025, the last priced event on record. It has raised $25.6 million across 2 recorded rounds; the latest was a $5.5 million early-stage round in Oct 2025.
PMV mark · valuation
$135.5M
Oct 2026
Priced at
its early-stage round
Dec 2025
Total raised
$25.6M
Last round
Early Stage VC
Oct 2025
Team — not yet on record
No current team members for GEn1E Lifesciences are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of GEn1E Lifesciences with a free account
·The complete investor list: 38 names
·Watch GEn1E Lifesciences: the Monday email on marks, rounds and moves
